![Fabrizio Pertusati](https://profiles-cardiff.imgix.net/attachments/8669?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Fabrizio Pertusati
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Fabrizio Pertusati
Darlithydd
Trosolwyg
Mae gennyf MSc mewn Cemeg Organig Ffisegol o Brifysgol Turin (synthesis a nodweddu syrffactyddion cationig) a PhD mewn cemeg organig anghymesur o Ysgol Cemeg Caerdydd, (atropisomeric bis-quinazolinones).
Cynhaliais fy hyfforddiant ôl-ddoethurol ym Mhrifysgol Emory (synthesis cyfnod solid o liwiau polymethine) ac yn labordy yr Athro George Olah, enillydd Gwobr Nobel , ym Mhrifysgol Southern California, lle rwy'n ennill arbenigedd mewn organofluorine, organoboron a chemeg polymer ).
Ers 2011, rwyf wedi bod yn gweithio yng ngrŵp Chris McGuigan lle roeddwn yn ymwneud â phrosiectau darganfod cyffuriau amrywiol.
Mae ymchwil yn fy ngrŵp yn cynnwys dylunio a synthesis moleciwlau bach fel therapiwteg yn erbyn Clefydau Prin (anhwylder cynhenid glycosylation, Niemann-Pick, Cystinosis a myopathi GNE), clefydau heintus, ac yn ddiweddar darganfod cyffuriau gwrthffyngol
Arbenigeddau Allweddol
- Organofluorine, organoffosfforws, cemeg carbohydradau.
- Dylunio a synthesis prodrugs ffosffad / ffosfforate o sgaffaldiau carbohydrad
- Cyffur trosiadol Darganfod
- Darganfod cyffuriau clefydau prin: anhwylderau rhyddhau GNE, Cystinosis a Niemann-Pick.
- Synthesis moleciwlau bach gyda gweithgareddau gwrthffyngol
Cyhoeddiad
2027
- Manis, C. et al., 2027. Bis(monoacylglycero)phosphate (BMP) as a circulating biomarker of lysosomal dysfunction in GNE myopathy. Clinica Chimica Acta 593 121244. (10.1016/j.cca.2026.121244)
2026
- Menezes, C. et al., 2026. Nucleoside analogue with thymidine nucleobase inhibits Leishmania infantum and depolarizes the plasma membrane potential in vitro. ACS Omega 11 (9), pp.14414–14425. (10.1021/acsomega.5c09199)
- Harsent, R. et al. 2026. Enterococcus spp. ability to form a dry surface biofilm: a route to persistence on environmental surfaces. Journal of Hospital Infection 167 , pp.23-33. (10.1016/j.jhin.2025.09.008)
2025
- Tisnerat, C. , Pertusati, F. and Serpi, M. 2025. Synthesis of triphosphate nucleoside prodrugs: γ‐ProTriPs. Current Protocols in Neuroscience 5 (12) e70291. (10.1002/cpz1.70291)
- Gambrill, B. et al. 2025. A novel multilayer antimicrobial urinary catheter material with antimicrobial properties. Materials Advances 6 , pp.1020-1030. (10.1039/d4ma01045k)
- Tisnerat, C. et al. 2025. Microwave-accelerated synthesis of novel triphosphate nucleoside prodrugs: Expanding the therapeutic arsenal of anticancer agents. Organic Letters 27 (1), pp.322-327. (10.1021/acs.orglett.4c04379)
2024
- Pertusati, F. et al. 2024. Fingolimod phosphoramidate prodrugs: Synthesis, photophysical characterisation and lipid bilayer interaction of fluorescent tagged Prodrug. Journal of Molecular Structure 1312 (2) 138614. (10.1016/j.molstruc.2024.138614)
- Gambrill, B. et al. 2024. Materials-based incidence of urinary catheter associated urinary tract infections and the causative micro-organisms: systematic review and meta-analysis. BMC Urology 24 (1) 186. (10.1186/s12894-024-01565-x)
- Serpi, M. , di Ciano, S. and Pertusati, F. 2024. Design, synthesis and biological evaluation of aryloxy thiophosphoramidate triesters of anticancer nucleoside analogues. Bioorganic and Medicinal Chemistry 103 117696. (10.1016/j.bmc.2024.117696)
- Alghamdi, R. , Pertusati, F. and Prokopovich, P. 2024. Poly-beta-amino-ester licofelone conjugates development for osteoarthritis treatment †. RSC Advances 14 (1), pp.15-28. (10.1039/d3ra04967a)
2023
- Serpi, M. et al. 2023. Synthesis, molecular docking and antibacterial activity of an oxadiazole-based lipoteichoic acid inhibitor and its metabolites. Journal of Molecular Structure 1278 134977. (10.1016/j.molstruc.2023.134977)
- Cook, S. R. et al. 2023. Investigating lysosomal and cellular phenotypes of the lysosomal disorder cystinosis. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.28-28. (10.1016/j.ymgme.2022.107061)
2022
- Pertusati, F. and Morewood, J. 2022. Synthesis of 2‐Acetamido‐1,3,4‐Tri‐O‐Acetyl‐2‐Deoxy‐D‐Mannopyranose ‐6‐Phosphate Prodrugs as potential therapeutic agents. Current Protocols 2 (8) e500. (10.1002/cpz1.500)
2021
- Vanden Avond, M. A. et al., 2021. The nucleotide prodrug CERC‐913 improves mtDNA content in primary hepatocytes from DGUOK‐deficient rats. Journal of Inherited Metabolic Disease 44 (2), pp.492-501. (10.1002/jimd.12354)
- Serpi, M. and Pertusati, F. 2021. An overview of ProTide technology and its implications to drug discovery. Expert Opinion on Drug Discovery 16 (10), pp.1149--1161. (10.1080/17460441.2021.1922385)
2020
- Pertusati, F. et al. 2020. Drug repurposing: phosphate prodrugs of anticancer and antiviral FDA-approved nucleosides as novel antimicrobials. Journal of Antimicrobial Chemotherapy 75 (10), pp.2864-2878. (10.1093/jac/dkaa268)
2019
- Pertusati, F. et al. 2019. A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF5) and pentafluoroethyl (C2F5) substituents: Improved antiproliferative agents against prostate cancer. European Journal of Medicinal Chemistry 180 , pp.1-14. (10.1016/j.ejmech.2019.07.001)
- Morozzi, C. et al. 2019. Targeting GNE myopathy: A dual prodrug approach for the delivery of N-acetylmannosamine 6-phosphate. Journal of Medicinal Chemistry 62 (17), pp.8178-8193. (10.1021/acs.jmedchem.9b00833)
2018
- Pileggi, E. , Serpi, M. and Pertusati, F. 2018. Preparation of pyrimidine alkenyl acyclic nucleoside phosphonoamidates. Current Protocols in Nucleic Acid Chemistry 74 (13-14) e56. (10.1002/cpnc.56)
- Pileggi, E. et al. 2018. Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. Bioorganic and Medicinal Chemistry 26 (12), pp.3596-3609. (10.1016/j.bmc.2018.05.034)
- Slusarczyk, M. , Serpi, M. and Pertusati, F. 2018. Phosphoramidates and phosphonamidates (ProTides) with antiviral activity. Antiviral Chemistry and Chemotherapy 26 , pp.1-31. (10.1177/2040206618775243)
2017
- Pertusati, F. et al. 2017. Phosphonoamidate prodrugs of C5-substituted pyrimidine acyclic nucleosides for antiviral therapy. Antiviral Research 143 , pp.262-268. (10.1016/j.antiviral.2017.04.013)
- Serpi, M. et al. 2017. Synthetic approaches for the preparation of phosphoramidate prodrugs of 2’-deoxypseudoisocytidine. ChemistryOpen 6 (3), pp.424-436. (10.1002/open.201700019)
- Bassetto, M. et al. 2017. Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents. MedChemComm 8 (7), pp.1414-1420. (10.1039/C7MD00164A)
- James, E. et al. 2017. Kinase-independent phosphoramidate S1P1 receptor agonist benzyl ether derivatives. Biorganic and Medicinal Chemistry Letters 27 (6), pp.1371-1378. (10.1016/j.bmcl.2017.02.011)
- Pertusati, F. et al. 2017. Synthesis and substrate-controlled reactions of 2,2′-unsaturated biquinazolinones. Tetrahedron 73 (1), pp.55-63. (10.1016/j.tet.2016.11.060)
2016
- Marinozzi, M. , Pertusati, F. and Serpi, M. 2016. λ5-Phosphorus-Containing α-Diazo Compounds (PCDCs): a valuable tool for accessing phosphorus-functionalized molecules. Chemical Reviews 116 (22), pp.13991-14055. (10.1021/acs.chemrev.6b00373)
- Serpi, M. , Ferrari, V. and Pertusati, F. 2016. Nucleosided derived antibiotics to fight microbial drug resistance: New utilities for an established class of drugs?. Journal of Medicinal Chemistry 59 (23), pp.10343-10382. (10.1021/acs.jmedchem.6b00325)
- Bassetto, M. et al. 2016. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer. European Journal of Medicinal Chemistry 118 , pp.230-243. (10.1016/j.ejmech.2016.04.052)
- Ferla, S. et al. 2016. Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety. Bioorganic and Medicinal Chemistry Letters 26 (15), pp.3636-3640. (10.1016/j.bmcl.2016.06.001)
- McGuigan, C. et al. 2016. Anti-flavivirus activity of different tritylated pyrimidine and purine nucleoside analogues. ChemistryOpen 5 (3), pp.227-235. (10.1002/open.201500216)
2015
- Pertusati, F. and McGuigan, C. 2015. Diastereoselective synthesis of P-chirogenic phosphoramidate prodrugs of nucleoside analogues (ProTides) via copper catalysed reaction. Chemical Communications 51 (38), pp.8070-8073. (10.1039/C5CC00448A)
- Pertusati, F. , McGuigan, C. and Serpi, M. 2015. Symmetrical diamidate prodrugs of nucleotide analogues for drug delivery. In: Current Protocols in Nucleic Acid Chemistry. Wiley-Blackwell. , pp.60:15.6.1-15.6.10. (10.1002/0471142700.nc1506s60)
- Ferrari, V. et al. 2015. Chemoselective N-deacetylation of protected nucleosides and nucleotides promoted by the Schwartz's reagent. Nucleosides, Nucleotides & Nucleic Acids 34 (11), pp.799-814. (10.1080/15257770.2015.1075552)
2014
- Toti, K. S. et al., 2014. Synthesis of an apionucleoside family and discovery of a prodrug with anti-HIV activity. Journal of Organic Chemistry 79 (11), pp.5097-5112. (10.1021/jo500659e)
- Pertusati, F. et al. 2014. PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer. European Journal of Medicinal Chemistry 78 , pp.259-268. (10.1016/j.ejmech.2014.03.051)
- McGuigan, C. et al. 2014. ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents. Bioorganic and Medicinal Chemistry 22 (9), pp.2816-2824. (10.1016/j.bmc.2014.02.056)
2013
- McGuigan, C. et al. 2013. Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. European Journal of Medicinal Chemistry 70 , pp.326-340. (10.1016/j.ejmech.2013.09.047)
2011
- Pertusati, F. , Serpi, M. and McGuigan, C. 2011. Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy. Antiviral Chemistry and Chemotherapy 22 (5), pp.181-203. (10.3851/IMP2012)
2007
- Pertusati, F. 2007. Synthesis of atropisomeric 2,2'-disubstituted-3,3'-quinazolin-4,4'-diones and their application in asymmetric synthesis. PhD Thesis , Cardiff University.
Adrannau llyfrau
- Pertusati, F. , McGuigan, C. and Serpi, M. 2015. Symmetrical diamidate prodrugs of nucleotide analogues for drug delivery. In: Current Protocols in Nucleic Acid Chemistry. Wiley-Blackwell. , pp.60:15.6.1-15.6.10. (10.1002/0471142700.nc1506s60)
Cynadleddau
- Cook, S. R. et al. 2023. Investigating lysosomal and cellular phenotypes of the lysosomal disorder cystinosis. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.28-28. (10.1016/j.ymgme.2022.107061)
Erthyglau
- Manis, C. et al., 2027. Bis(monoacylglycero)phosphate (BMP) as a circulating biomarker of lysosomal dysfunction in GNE myopathy. Clinica Chimica Acta 593 121244. (10.1016/j.cca.2026.121244)
- Menezes, C. et al., 2026. Nucleoside analogue with thymidine nucleobase inhibits Leishmania infantum and depolarizes the plasma membrane potential in vitro. ACS Omega 11 (9), pp.14414–14425. (10.1021/acsomega.5c09199)
- Harsent, R. et al. 2026. Enterococcus spp. ability to form a dry surface biofilm: a route to persistence on environmental surfaces. Journal of Hospital Infection 167 , pp.23-33. (10.1016/j.jhin.2025.09.008)
- Tisnerat, C. , Pertusati, F. and Serpi, M. 2025. Synthesis of triphosphate nucleoside prodrugs: γ‐ProTriPs. Current Protocols in Neuroscience 5 (12) e70291. (10.1002/cpz1.70291)
- Gambrill, B. et al. 2025. A novel multilayer antimicrobial urinary catheter material with antimicrobial properties. Materials Advances 6 , pp.1020-1030. (10.1039/d4ma01045k)
- Tisnerat, C. et al. 2025. Microwave-accelerated synthesis of novel triphosphate nucleoside prodrugs: Expanding the therapeutic arsenal of anticancer agents. Organic Letters 27 (1), pp.322-327. (10.1021/acs.orglett.4c04379)
- Pertusati, F. et al. 2024. Fingolimod phosphoramidate prodrugs: Synthesis, photophysical characterisation and lipid bilayer interaction of fluorescent tagged Prodrug. Journal of Molecular Structure 1312 (2) 138614. (10.1016/j.molstruc.2024.138614)
- Gambrill, B. et al. 2024. Materials-based incidence of urinary catheter associated urinary tract infections and the causative micro-organisms: systematic review and meta-analysis. BMC Urology 24 (1) 186. (10.1186/s12894-024-01565-x)
- Serpi, M. , di Ciano, S. and Pertusati, F. 2024. Design, synthesis and biological evaluation of aryloxy thiophosphoramidate triesters of anticancer nucleoside analogues. Bioorganic and Medicinal Chemistry 103 117696. (10.1016/j.bmc.2024.117696)
- Alghamdi, R. , Pertusati, F. and Prokopovich, P. 2024. Poly-beta-amino-ester licofelone conjugates development for osteoarthritis treatment †. RSC Advances 14 (1), pp.15-28. (10.1039/d3ra04967a)
- Serpi, M. et al. 2023. Synthesis, molecular docking and antibacterial activity of an oxadiazole-based lipoteichoic acid inhibitor and its metabolites. Journal of Molecular Structure 1278 134977. (10.1016/j.molstruc.2023.134977)
- Pertusati, F. and Morewood, J. 2022. Synthesis of 2‐Acetamido‐1,3,4‐Tri‐O‐Acetyl‐2‐Deoxy‐D‐Mannopyranose ‐6‐Phosphate Prodrugs as potential therapeutic agents. Current Protocols 2 (8) e500. (10.1002/cpz1.500)
- Vanden Avond, M. A. et al., 2021. The nucleotide prodrug CERC‐913 improves mtDNA content in primary hepatocytes from DGUOK‐deficient rats. Journal of Inherited Metabolic Disease 44 (2), pp.492-501. (10.1002/jimd.12354)
- Serpi, M. and Pertusati, F. 2021. An overview of ProTide technology and its implications to drug discovery. Expert Opinion on Drug Discovery 16 (10), pp.1149--1161. (10.1080/17460441.2021.1922385)
- Pertusati, F. et al. 2020. Drug repurposing: phosphate prodrugs of anticancer and antiviral FDA-approved nucleosides as novel antimicrobials. Journal of Antimicrobial Chemotherapy 75 (10), pp.2864-2878. (10.1093/jac/dkaa268)
- Pertusati, F. et al. 2019. A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF5) and pentafluoroethyl (C2F5) substituents: Improved antiproliferative agents against prostate cancer. European Journal of Medicinal Chemistry 180 , pp.1-14. (10.1016/j.ejmech.2019.07.001)
- Morozzi, C. et al. 2019. Targeting GNE myopathy: A dual prodrug approach for the delivery of N-acetylmannosamine 6-phosphate. Journal of Medicinal Chemistry 62 (17), pp.8178-8193. (10.1021/acs.jmedchem.9b00833)
- Pileggi, E. , Serpi, M. and Pertusati, F. 2018. Preparation of pyrimidine alkenyl acyclic nucleoside phosphonoamidates. Current Protocols in Nucleic Acid Chemistry 74 (13-14) e56. (10.1002/cpnc.56)
- Pileggi, E. et al. 2018. Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. Bioorganic and Medicinal Chemistry 26 (12), pp.3596-3609. (10.1016/j.bmc.2018.05.034)
- Slusarczyk, M. , Serpi, M. and Pertusati, F. 2018. Phosphoramidates and phosphonamidates (ProTides) with antiviral activity. Antiviral Chemistry and Chemotherapy 26 , pp.1-31. (10.1177/2040206618775243)
- Pertusati, F. et al. 2017. Phosphonoamidate prodrugs of C5-substituted pyrimidine acyclic nucleosides for antiviral therapy. Antiviral Research 143 , pp.262-268. (10.1016/j.antiviral.2017.04.013)
- Serpi, M. et al. 2017. Synthetic approaches for the preparation of phosphoramidate prodrugs of 2’-deoxypseudoisocytidine. ChemistryOpen 6 (3), pp.424-436. (10.1002/open.201700019)
- Bassetto, M. et al. 2017. Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents. MedChemComm 8 (7), pp.1414-1420. (10.1039/C7MD00164A)
- James, E. et al. 2017. Kinase-independent phosphoramidate S1P1 receptor agonist benzyl ether derivatives. Biorganic and Medicinal Chemistry Letters 27 (6), pp.1371-1378. (10.1016/j.bmcl.2017.02.011)
- Pertusati, F. et al. 2017. Synthesis and substrate-controlled reactions of 2,2′-unsaturated biquinazolinones. Tetrahedron 73 (1), pp.55-63. (10.1016/j.tet.2016.11.060)
- Marinozzi, M. , Pertusati, F. and Serpi, M. 2016. λ5-Phosphorus-Containing α-Diazo Compounds (PCDCs): a valuable tool for accessing phosphorus-functionalized molecules. Chemical Reviews 116 (22), pp.13991-14055. (10.1021/acs.chemrev.6b00373)
- Serpi, M. , Ferrari, V. and Pertusati, F. 2016. Nucleosided derived antibiotics to fight microbial drug resistance: New utilities for an established class of drugs?. Journal of Medicinal Chemistry 59 (23), pp.10343-10382. (10.1021/acs.jmedchem.6b00325)
- Bassetto, M. et al. 2016. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer. European Journal of Medicinal Chemistry 118 , pp.230-243. (10.1016/j.ejmech.2016.04.052)
- Ferla, S. et al. 2016. Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety. Bioorganic and Medicinal Chemistry Letters 26 (15), pp.3636-3640. (10.1016/j.bmcl.2016.06.001)
- McGuigan, C. et al. 2016. Anti-flavivirus activity of different tritylated pyrimidine and purine nucleoside analogues. ChemistryOpen 5 (3), pp.227-235. (10.1002/open.201500216)
- Pertusati, F. and McGuigan, C. 2015. Diastereoselective synthesis of P-chirogenic phosphoramidate prodrugs of nucleoside analogues (ProTides) via copper catalysed reaction. Chemical Communications 51 (38), pp.8070-8073. (10.1039/C5CC00448A)
- Ferrari, V. et al. 2015. Chemoselective N-deacetylation of protected nucleosides and nucleotides promoted by the Schwartz's reagent. Nucleosides, Nucleotides & Nucleic Acids 34 (11), pp.799-814. (10.1080/15257770.2015.1075552)
- Toti, K. S. et al., 2014. Synthesis of an apionucleoside family and discovery of a prodrug with anti-HIV activity. Journal of Organic Chemistry 79 (11), pp.5097-5112. (10.1021/jo500659e)
- Pertusati, F. et al. 2014. PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer. European Journal of Medicinal Chemistry 78 , pp.259-268. (10.1016/j.ejmech.2014.03.051)
- McGuigan, C. et al. 2014. ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents. Bioorganic and Medicinal Chemistry 22 (9), pp.2816-2824. (10.1016/j.bmc.2014.02.056)
- McGuigan, C. et al. 2013. Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. European Journal of Medicinal Chemistry 70 , pp.326-340. (10.1016/j.ejmech.2013.09.047)
- Pertusati, F. , Serpi, M. and McGuigan, C. 2011. Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy. Antiviral Chemistry and Chemotherapy 22 (5), pp.181-203. (10.3851/IMP2012)
Gosodiad
- Pertusati, F. 2007. Synthesis of atropisomeric 2,2'-disubstituted-3,3'-quinazolin-4,4'-diones and their application in asymmetric synthesis. PhD Thesis , Cardiff University.
Ymchwil
Mae'r ymchwil yn y grŵp yn bennaf mewn cemeg organig synthetig gyda'r nod o ddatrys ystod o broblemau cemeg meddyginiaethol ym meysydd:
Clefydau Prin
- Clefydau Storio Lysosomaidd: Cystinosys, Nieman-Pick, Mucolipidoses IV.
Camgymeriadau metabolaeth cynhenid
- Cyfansoddion carbohydrad ar gyfer trin Anhwylder Cynhenid Glycosylation.
- Mae analogau niwcleosid yn prodrugs ar gyfer trin Syndrom Depletion Mitocondrial.
Clefydau heintus
- Synthesis o niwcleosidau a sgaffaldiau di-niwcleosid fel asiantau gwrthfacterol newydd.
- heterocycles fflworinated fel asiantau gwrthffyngol
- Moleciwlau bach fflworinedig fel cyffuriau antileishmaniasys newydd.
Cemeg synthetig
-Synthesis o ffosffad niwcleosid acyclic newydd a sgaffaldiau ffosfforsad fel cyffuriau gwrthffyngol ac antiparasitig.
-Datblygu methodolegau synthetig ar gyfer paratoi diasteroselective ac enantioselective cyfansoddion organophosphorus trwy fferyllfeydd P(V) a P(III).
Cydweithredwyr
Clefydau Prin:
- Dr Emyr Lloyd Evans (Clefyd storio Lysosomal, Ysgol y Biowyddorau)
- Yr Athro Hanns Lockmuller (Prifysgol Ottawa)
- Yr Athro Pierluigi Caboni (Prifysgol Cagliari)
- Yr Athro Rudiger Horskorte (Prifysgol Martin-Luther-Halle-Wittenberg)
- Yr Athro Paula Videira (Ysgol Wyddoniaeth Nova, Lisbon)
Clefydau heintus
Darganfod Cyffuriau Gwrthffyngol
- Yr Athro Elaine Bignell (Canolfan MRC ar gyfer Mycoleg Feddygol, Prifysgol Exeter)
Darganfod Cyffuriau Antiparasitig (Leishmaniasis)
- Dr. Samanta Borborema (Canolfan Parasitoleg a Mycoleg, Instituto Adolfo Lutz, São Paulo, Brasil)
I gael rhagor o wybodaeth am brosiectau ymchwil penodol sydd ar gael gyda Dr Fabrizio Pertusati, darllenwch adran Synthesis Moleciwlaidd ein themâu prosiect ymchwil.
Addysgu
- CHT223 Cymwysiadau Diwydiannol Biocatalysis
- Technegau CHT352 mewn Darganfod Cyffuriau
- Targedau Cyffuriau CHT353
- Datblygiad Cyffuriau CHT354 o Labordy i Glinig
- Colocwiwm CHT216
- CH5130 Cyflwyniad i Ddatblygu Cyffuriau
- Prosiect CH3325
- CH5207 Intoduction i gemeg bywyd
Bywgraffiad
Cefais fy ngradd MSc mewn cemeg organig ffisegol o Brifysgol Turin (synthesis a nodweddu syrffactyddion cationig). Ar ôl treulio tair blynedd yn y diwydiant PCB fel gwyddonydd fformiwleiddiwr, cefais fy PhD mewn cemeg organig synthetig (Ysgol Cemeg Caerdydd, bis-quinazolinones atropisomeric fel cynorthwywyr ar gyfer synthesis anghymesur). Cynhaliais fy hyfforddiant ôl-ddoethurol ym Mhrifysgol Emory (synthesis cyfnod solid o liwiau polymethine) ac yn labordy yr Athro George Olah, ym Mhrifysgol Southern California (organofluorine, organoboron a chemeg polymer).
Ers 2011, rydw i wedi bod yn gweithio yng ngrŵp Chris McGuigan lle roeddwn i'n ymwneud â phrosiectau cemeg meddyginiaethol amrywiol yn rhychwantu synthesis diastereoselective o prodrugs, niwcleosidau (cylchol ac acyclic), i wrthweithydd derbynyddion androgenaidd fflworinedig ar gyfer trin canser y prostad, a dylunio a synthesis cyfansoddion newydd sy'n gweithredu ar y System Nerfol Ganolog).
Yn 2016, cefais fy nyrchafu yn Gymrawd Ymchwil mewn cemeg feddyginiaethol. Fy niddordebau ymchwil cyfredol yw synthesis gwrthfiotigau fflworineiddio newydd ar gyfer trin heintiau bacteriol Gram-positif a ffurfio bioffilm (mewn cydweithrediad â'r Athro Hans Steenackers ym Mhrifysgol Leuven) ac mewn anhwylderau cynhenid glycosylation. Mae gennyf ddiddordeb hefyd mewn dylunio cyffuriau ar gyfer trin anhwylderau storio lysosomaidd (Niemann-Pick, Huntington) mewn cydweithrediad â'r Athro Lloyd-Evans (Ysgol Biowyddoniaeth Caerdydd).
Aelodaethau proffesiynol
- Member of Scientific Advisory Board of Ichorion Therapeutics (2017-2018)
- Member of Glycobiology Society
Pwyllgorau ac adolygu
- Reviewer for The following Journal.
Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, The journal of Organic Chemistry, ChemMedChem, Molecules, Bioorganic & Medicinal Chemistry Letters, Journal of Fluorine Chemistry, Organic Letters and Dyes and Pigments.
- Grant Reviewer: MRC-fellowship.
News articles
Contact Details
[email protected]
+44 29225 12036
Y Prif Adeilad, Llawr 1, Ystafell 1.89C, Plas y Parc, Caerdydd, CF10 3AT
+44 29225 12036
Y Prif Adeilad, Llawr 1, Ystafell 1.89C, Plas y Parc, Caerdydd, CF10 3AT
Themâu ymchwil
Arbenigeddau
- Cemeg organig
- Synthesis cemegol organig
- Darganfod Cyffuriau Trosiadol
